Salud financiera de hoja de balance de Replimune Group
Salud financiera controles de criterios 5/6
Replimune Group tiene unos fondos propios totales de $465.2M y una deuda total de $29.2M, lo que sitúa su ratio deuda/fondos propios en 6.3%. Sus activos y pasivos totales son $562.4M y $97.2M respectivamente.
Información clave
10.5%
Ratio deuda-patrimonio
US$44.43m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$466.35m |
| Patrimonio | US$421.54m |
| Total pasivo | US$111.39m |
| Activos totales | US$532.93m |
Actualizaciones recientes sobre salud financiera
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Recent updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Análisis de la situación financiera
Pasivos a corto plazo: REPLLos activos a corto plazo ($508.2M) de la empresa superan a sus pasivos a corto plazo ($39.8M).
Pasivo a largo plazo: REPLLos activos a corto plazo ($508.2M) superan a sus pasivos a largo plazo ($57.4M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: REPL tiene más efectivo que su deuda total.
Reducción de la deuda: REPLha pasado de 0% a 6.3% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: REPL tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: REPL dispone de suficiente liquidez para 2.2 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 32.5% cada año.